In February 2017, Novartis entered into an indefinite employment agreement with Dr. Phil Smith. With the recent advances in photoredox chemistry, Novartis believed that Dr. Smith could advise the company as to how Novartis might approach certain organic chemistry matters, including iridium photocatalysis.
The agreement was for an indefinite term, and paid Dr. Smith 9,000 USD per month. In March 2017, Novartis had its first meeting with Dr. Smith under this agreement. Following this initial meeting, Novartis determined that business conditions completely unrelated to Dr. Smith's skills in the laboratory had changed, and that Novartis financial conditions required the decision to not engage further.
As there was no contract and happily Dr. Smith could be terminated for any reason, payments were stopped immediately in March 2017.
with no apologies to Novartis